Kornimate/medical-research-clean huggingface dataset:
efficacy of high-dose dual therapy vs bismuth-containing quadruple therapy for rescue treatment of hp infection

Conditions: Helicobacter Pylori Infection

Summary: up to now, there is few randomized, large scale study prospectively and simultaneously comparing the efficacy, adverse effects and patient adherence of high-dose dual therapy (hddt) and bismuth-containing quadruple therapy (bqt) as rescue regimens for h. pylori eradication. the aims of this study are: 1. to compare the efficacy of hddt, and bqt as rescue regimen in h. pylori eradication; 2. to compare the patient adherence and adverse effects of these treatment regimens; 3. to investigate factors that may influence h. pylori eradication by these treatment regimens.

participants, aged ≥ 20, having h. pylori-positive chronic gastritis with/without peptic ulcers (duodenal or gastric ulcers) will be recruited. all undergo endoscopy with biopsy for rapid urease teat, histology, and bacterial culture before treatment. four to eight weeks after termination of treatment, h. pylori infection status will be examined by the 13c-urea breath test. the cyp2c19 genotype of each participant will be analyzed by the polymerase chain reaction-based restriction fragment length polymerase (pcr-rflp) method. a computed generated random numbers sequence will be blocked into two subgroups, say a, and b. if the patients failed anti-h. pylori therapy previously, they will be invited to enter this study for evaluating the efficacy of these rescue regimens. participant who meet the inclusion criteria and do not have any one of the exclusion criteria will be randomized to receive one of the following regimens: group a- hddt (rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days); group b- bqt ( rabeprazole 20 mg qid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days); all participants will be asked to complete a questionnaire and to record symptoms and drug consumption daily during the treatment period. post-treatment, the participants will be followed up at the outpatients clinic to investigate patient adherence and adverse effect of treatment.

Eligibility criteria:
inclusion criteria: 1. participants having h. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy. exclusion criteria: 1. pregnant or nursing woman 2. serious concomitant illness and malignant tumor of any kind 3. history of hypersensitivity to test drugs 4. serious bleeding during the course of the ulcer 5. previous gastric surgery 6. receiving bismuth salts, ppis, or antibiotics in the previous month.

Keywords: helicobacter pylori high dose dual therapy bismuth-containing quadruple therapy antibiotic resistance
effect of "nicotinamide mononucleotide" (nmn) on cardiometabolic function

Conditions: Glucose Metabolism Disorders

Summary: the purpose of the study is to understand the effect of the dietary supplement "nicotinamide mononucleotide" on metabolic health in people.

this study is is looking at the effect of the dietary supplement "nicotinamide mononucleotide" (nmn) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. accordingly, the investigators will evaluate the effect of nmn on how well the hormone insulin works to control blood sugar. the investigators will also look at the effects of nmn on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. data from studies conducted in rodents have shown that nmn supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.

Eligibility criteria:
inclusion criteria: * postmenopausal women 55-75 years old * bmi 25.0-44.9 kg/m² * fasting plasma glucose concentration ≥100 mg/dl, ogtt 2 hour glucose ≥ 140 mg/dl, hba1c ≥5.7%, or homa-ir ≥2.5 exclusion criteria: * diabetes * premenopausal or menopause \<1 year * persons who have received hormone replacement therapy within the past 6 months * persons who take vitamin b supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period. * structured exercise: ≥75 min/wk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min/wk of low intensity physical activity (e.g., brisk walking). * unstable weight (\>3% change during the last 2 months before entering the study) * significant organ system dysfunction or disease * present cancer or history of cancer that has been in remission for \<5 years * polycystic ovary syndrome * major psychiatric illness * use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study * metal implants * smokes cigarettes * persons who consume \>14 units of alcohol per week * unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
study of combined therapy of aspirin and "ivig-sn" in kawasaki disease

Conditions: Kawasaki Disease

Summary: the purpose of this study is to evaluate the safety, efficacy and of immune globulin intravenous (human) ivig-sn™ in subjects with kawasaki diseases.

this clinical trial was designed as a multicenter, single-arm, and open-label clinical trial. evaluate the incidence of coronary artery lesions in the 7th week of ivig-sn administration, compared to the incidence of coronary artery lesions among untreated kawasaki patients, to prove the superior efficacy of ivig-sn.

Eligibility criteria:
inclusion criteria: 1. pediatric patients aged 6 months - 5 years 2. case definition for complete kd: fever (≥ 38.5°c) for ≥ 5 days (but less than 10 days), 4/5 standard clinical criteria 3. case definition for incomplete kd: fever ≥ 5 days(but less than 10 days) and 3 clinical criteria plus coronary artery lesion on echocardiogram. 4. subjects whose parents or legally acceptable representative (lar) gave voluntary written consent to participate in this clinical trial exclusion criteria: 1. those whose blood test results show abnormalities of significance as follows : platelet count \< 100,000/mm3, wbc count \<3,000 cells/mm3,those whose hemogloblin, hematocrit or red blood cell count exceed 30% of the upper limit of the normal range or are 30% below the lower limit of the normal range. 2. those who have been administered other clinical product in the last 30 days after this clinical trial commenced 3. those who have been administered tnf alpha or steroid within 48 hours after being administered the test product 4. those who plan to be inoculated with live vaccine during the clincial trial period 5. those considered difficult to participate in clinical trial due to serious chronic diseases(e.g., cardiovascular diseases except controllable hypertension, diseases of the respiratory system concurrent with respiratory failure, metabolic disease, kidney dysfunction, hemoglobinopathy, etc.) 6. those who have been administered an immunosuppressant or immune modifying drug in the last 3 months before the innoculation with the test product 7. those who are hiv-positive or have immune dysfunctions including immunodeficiency 8. those who have previously exhibited hypersensitivity or shock to ivig agents 9. patients with underlying liver disease or liver dysfunction with known etiology. 10. patients with kidney dysfunction, whose creatinine level is found to be over 2 times higher than the upper limit of the normal ranges in a screening test 11. those who have -- or previously had -- a malignant tumor 12. those who have previously been diagnosed with iga deficiency 13. those found unsuitable for undergoing the tests
pulsatile and steady state hemodynamics in diastolic heart failure

Conditions: Diastolic Heart Failure

Summary: over the past few years, there has been a growing appreciation that a large number of patients with heart failure have a relatively normal (or preserved) ejection fraction (nfnef). epidemiologically, hfnef is most prevalent among elderly women, most of whom have hypertension, diabetes, or both and often coronary artery disease (cad). increased arterial stiffness and/or wave reflections have been described in the same patient groups. therefore, the investigators speculate that pulsatile hemodynamics, representing arterial stiffness and/or arterial wave reflections, 1) may be altered in hfnef patients, 2) this may contribute to pathophysiology of hfnef, and 3) this may be used for the diagnosis of the syndrome.


Eligibility criteria:
inclusion criteria: * exertional dyspnea * undergoing heart catheterization for diagnosis or exclusion of coronary artery disease * normal ef (\> 50%) exclusion criteria: * atrial fibrillation * more than mild valvular heart disease * pericardial disease * no informed consent

Keywords: arterial stiffness arterial wave reflections diastolic heart failure
buzzy application during heel blood collection in the newborn

Conditions: Buzzy

Summary: objective the aim of this study was to evaluate the effects of buzzy device application during heel prick blood collection on pain level and comfort in newborns. method. the study was conducted in a family health center affiliated to the public health directorate of a province in eastern turkey between september and november 2024 using a randomized controlled experimental design. the study sample consisted of 80 newborn infants born at 37-42 weeks gestational age and within the first 28 days of birth (buzzy group: n = 40, control group: n = 40). the buzzy group was treated by placing the buzzy device approximately 30 seconds before heel prick blood collection. in the control group, routine heel prick was performed without any application. neonatal introduction form, neonatal infant pain scale and neonatal comfort behavior scale were used for data collection.


Eligibility criteria:
inclusion criteria: * those in the neonatal period between 0-28 days, * voluntary participation of the parent, * between 37-42 weeks of gestational age * babies with vital signs within normal limits exclusion criteria: * the integrity of the skin in the area where the device was to be implanted was compromised, * nerve damage or deformity in the extremity to be heel bled, * genetic - with a congenital anomaly or congenital metabolic disorder, * undergoing cardiopulmonary resuscitation, * no heel prick on the first attempt, * with osteogenesis imperfecta and infants given analgesics in the last 6 hours
acl reconstruction with/without all reconstruction

Conditions: ACL Injury; ALL

Summary: this study will compare anterior cruciate reconstruction with or without anterolateral ligament reconstruction in patients with acl injury. the purpose of this study is evaluate if addition of allr to aclr provides better clinical, radiological and laboratory outcomes.

this study compare acl reconstruction and additional tenodesis or all recontruction described by arnold. patients will be randomized fot this tree group and surgeon will be blinded. anterolateral ligament reconstruction could play a role in augmenting rotational stability in the acl-reconstructed knee and are most likely to benefit hyperlax patients, revision cases, pivoting athletes, and those with ikdc grade iii pivot shifts. in our study we will would like to confirm this hypothesis.

Eligibility criteria:
inclusion criteria: - primary acl injury exclusion criteria: * no informed consent to participate in the study * age under 18 years or above 65 * multilligament injury or single plane knee instability (medial, lateral) * another musculoskeletal disorders in lower limb * lower limb deformity requiring axis correction below 4o or above 12.5o * joints inflammatory diseases * asa score \> ii

Keywords: acl, all
9000 urethra study: a study about urethroplasty for urethral stricture disease

Conditions: Urethral Stricture

Summary: it has been demonstrated that urethroplasty should be considered the gold standard treatment for urethral stricture disease as it yields higher long-term success rates than endoscopic treatment options such as direct vision internal urethrotomy (dviu) or dilation. many data about these procedures exist, although most of the publications about urethroplasty are retrospective and involve a tremendous risk of bias. to address these issues, this study is designed to prospectively gain evidence about this matter in all patient subgroups facing a potential treatment with urethroplasty: native men, native women, transmen, transwomen and children.


Eligibility criteria:
inclusion criteria: * voluntarily signed written informed consent according to the rules of good clinical practice (declaration of helsinki) and national regulations. * patient age ≥ 6 years. * if a patient reaches the age of 18 years, he or she will have to provide a new voluntarily signed written informed consent. all patients reaching the age of 18 years will be contacted by the principal investigator or subinvestigator to provide a new voluntarily signed written informed consent. exclusion criteria: - absence of signed written informed consent and thus a patient unwilling to participate.

Keywords: urethral stricture disease urethral stricture urethra urethroplasty
electroacupuncture modulates spms metabolism and respiratory symptoms in patients with sepsis complicating ards

Conditions: Sepsis; Acute Respiratory Distress Syndrome

Summary: in this interventional clinical trial, researchers will administer electroacupuncture versus sham electroacupuncture to sepsis patients with ards and collect objective outcome measures. the study will be divided into 2 groups. the ea group will receive electroacupuncture and the sham-ea group will receive sham electroacupuncture. the purpose of this study is to investigate the effect of electroacupuncture on the synthesis of spms in sepsis patients with ards.


Eligibility criteria:
inclusion criteria: 1. males or females over the age of 18; 2. diagnosis meets spesis 3 criteria for sepsis; 3. the diagnosis meets the berlin diagnostic criteria for ards; 4. ards was diagnosed within 48h; 5. capable of understanding the purpose and risk of the study; 6. patients or proxy must give written informed consent before any assessment is performed. exclusion criteria: 1. ards was diagnosed 48h later; 2. pregnancy, lactation or perinatal period; 3. malignant tumor; 4. severe liver failure or kidney failure; 5. predicted mortality risk of patients within 24h\>80%; 6. severe end-stage lung disease; 7. ecmo patients are undergoing implementation; 8. hiv seropositive or syphilis seropositive; 9. any clinical-relevant condition that might affect study participation and/or study results; 10. participation in any other intervention trial; 11. unwillingness or inability to following the study protocol in the investigators opinion.
comparison of two thoracic manipulation techniques to improve neck pain

Conditions: Neck Pain

Summary: this study is designed to compare the short-term effects of two different thoracic spine thrust manipulation techniques on neck range-of-motion, pain, and self-reported disability in people with neck pain. the null hypothesis is that there will be no differences between the two manipulation techniques for short-term effects on neck range-of-motion, pain, and self-reported disability in people with neck pain.

patients will be involved in the study over a 4 week period. each participant will be asked to attend 4 sessions, with one week in between each session as follows: week 0 = baseline assessment and treatment 1; week 1= treatment 2; week 2 = treatment 3; and week 4 = follow-up assessment. patients who meet the inclusion/exclusion criteria will be randomized to either a supine or prone thoracic spine thrust manipulation intervention.

Eligibility criteria:
inclusion criteria: * between 22 and 50 years of age * primary complaint of neck pain with or without symptoms that spread down into one arm * overall rating of neck pain intensity is at least 3/10; the overall rating is the overall average of the participant's rating of current, least, and worst pain experienced over the previous 24 hours on separate numeric pain rating scales where 0 corresponds to "no pain" and 10 corresponds to "worst pain possible". * neck disability index (ndi) score \> 10 points (measure of self-reported disability with a 0 to 50 point scale where higher scores indicate higher levels of disability). * proficient in speaking and reading english to complete outcome questionnaires exclusion criteria: * neck pain related to a motor vehicle accident or other trauma within the previous 6 weeks * neck pain that spreads down into both arms * low back pain or thoracic origin of pain * nerve root involvement; defined as the presence of two or more neurological findings (e.g. decreased strength, diminished deep tendon reflex, or decreased sensation) at the same nerve root level * diagnosis of cervical spine stenosis (narrowing of the central canal that contains the spinal cord) * history of spinal tumors, spinal infection, cervical spine fracture, or previous neck surgery * pending legal action related to current episode of neck pain * contraindications to thoracic spine thrust manipulation 1. serious pathologies or conditions (tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis, history of prolonged steroid use) 2. hyperreflexia 3. unsteadiness during gait 4. nystagmus 5. loss of visual acuity 6. impaired sensation of the face 7. altered taste 8. the presence of pathological reflexes 9. pregnancy or considering pregnancy

Keywords: neck pain thoracic spine manipulation range of motion disability
the effect of esmolol on clinical prognosis of patients with severe sepsis

Conditions: Severe Sepsis

Summary: the purpose of this study was to investigate the effect of esmolol on hemodynamic parameters,tissue perfusion and the clinical prognosis of patients with severe sepsis

enrollment:151 patients inclusion criteria: (1) age \> 18 years; (2) severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to campaign to save septic patients: 2008 treatment guidelines for severe sepsis and septic shock, who (3) mechanical ventilation via endotracheal intubation with a tidal volume of 6 ml/kg; and (4) satisfactory sedation and analgesic treatment, with hr \> 100 bpm.

Eligibility criteria:
inclusion criteria: * age \> 18 years; * severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to campaign to save septic patients: 2008 treatment guidelines for severe sepsis and septic shock, * mechanical ventilation via endotracheal intubation with a tidal volume of 6 ml/kg; * satisfactory sedation and analgesic treatment, with hr \> 100 bpm. exclusion criteria: * pre-existing cardiac dysfunction, valvular heart disease, high-degree atrioventricular block; * acute or chronic pulmonary heart disease; * a history of serious asthma; * chronic renal insufficiency; * cancer, autoimmune diseases, or contraindications for placement of deep venous catheter; * insulin-dependent diabetes.
statistical analysis of vlagtwedde-vlaardingen data set

Conditions: Asthma; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease

Summary: to determine the effects in early adulthood of asthma, increased bronchial responsiveness, markers of allergy and smoking on pulmonary function level and the effects of these same risk factors on subsequent decline in pulmonary function, because these early adult factors presumably profoundly influence the risk for chronic obstructive pulmonary disease.

design narrative: the questions studied included whether the above named risk factors reduced the maximally attained level of pulmonary function in early adulthood, foreshortened the postulated stability of level of pulmonary function between age 18 and 35 and/or unfavorably affected subsequent decline in level of pulmonary function. fev1/h2, vc/h2 and fev1/ivc were studied, using graphic smooth techniques and regression analyses techniques on both cross-sectional and longitudinal datasets. in addition, the investigators tested the hypothesis stating that early adult symptoms of asthma, increased bronchial responsiveness, markers of allergy influenced who became a smoker, influenced the amount smoked and/or influenced who stopped smoking relatively early in adult life, using logistic regression analyses and survival analyses. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
clinical study of aldurazyme in patients with mucopolysaccharidosis (mps) i

Conditions: Mucopolysaccharidosis I; Hurlers Syndrome; Hurler-Scheie Syndrome

Summary: this study is being conducted to demonstrate the safety and clinical efficacy of aldurazyme treatment in mps i patients


Eligibility criteria:
inclusion criteria: * the patient had a documented diagnosis of mps i confirmed by measurable clinical signs and symptoms of mps i and a fibroblast or leukocyte alpha-l-iduronidase enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory. * female patients of childbearing potential had a negative pregnancy test (urine-beta-human chorionic gonadotropin (hcg)) at baseline (all female patients of childbearing potential and sexually mature male patients were advised to use a medically accepted method of contraception throughout the study). * the patient was capable of standing independently for 6 minutes and walking a minimum of 5 meters within 6 minutes. * the patient was capable of performing a reproducible fvc maneuver. * the patient had a baseline fvc value that was less than or equal to 80% of the patient's predicted normal fvc value based on polgar predicted values for standing height for children 5 through 7 years of age and the hankinson predicted values for ages 8 and above. exclusion criteria: * the patient had undergone a tracheostomy. * the patient had previously undergone a bone marrow transplantation. * the patient was pregnant or lactating. * the patient has received an investigational drug within 30 days prior to study enrollment. * the patient had a medical condition, serious intercurrent illness, or other extenuating circumstance that could have significantly interfered with study compliance including all prescribing evaluations and follow-up activities. * the patient had a known hypersensitivity to rhidu or to components of the active or placebo test solutions.